Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors wi
The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand that one o
Exelixis, an oncology-focused company, has reported a sixth consecutive profitable year in 2022, with about 30% revenue growth due to increased sales of its drug, cabozantinib. EXEL reported total rev

3 No-Brainer Stocks to Buy With $200 Right Now

05:21am, Wednesday, 21'st Jun 2023
Every correction and bear market in the major stock indexes has marked an ideal buying opportunity for long-term investors. These three phenomenal businesses have the perfect blend of competitive adva
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Revenue-generating products like Cabometyx and strategic partnerships with industry leaders, such as Genentech, contribute to Exelixis' impressive financial performance and market presence. Exelixis'

2 Under-the-Radar Biotech Stocks to Buy in 2023

09:53am, Wednesday, 24'th May 2023
Exelixis and Sarepta are relatively small players in the highly competitive biotech industry. Both drugmakers have found success by focusing most of their efforts on niche areas.
Axsome has several catalysts in the works that could boost its stock price. Exelixis is working on new drugs to expand its footprint in oncology.
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Exelixis (EXEL) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.21 per share a year ago.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
The consensus price target hints at a 36.5% upside potential for Exelixis (EXEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Farallon isn't an activist investor, but it won't shy away from a battle if necessary.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE